Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenoviral cancer vaccine PF-06936308

A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	PF 06936308 PF-06936308 PF06936308

adenoviral cancer vaccine PF-06936308

Search NCI's Drug Dictionary